Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Status:
RECRUITING
Trial end date:
2034-04-01
Target enrollment:
Participant gender:
Summary
This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma.
Phase:
PHASE3
Details
Lead Sponsor:
The Lymphoma Academic Research Organisation
Collaborators:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea Lymphoma Study Association Swiss Cancer Institute